efficacy. We will concentrate on the effects of salmeterol and formoterol rather than on the potential adverse effects associated with the regular use of short-acting 02-agonists, about which so much has been written already. [6] [7] [8] [9] The data presented herein are the product of a comprehensive literature search that was extended to include an on-line search of all relevant databases as of July 1994.
DOES REGULAR DRUG THERAPY WITH INHALED LONG-ACTING 02-AGONISTS IMPROVE OVERALL CONTROL OF BRONCHIAL ASTHMA?
In a study by Sears et al, an apparent deterioration in asthma control was related to regular use of inhaled fenoterol, a short-acting /2-agonist unavailable in the United States. The authors generalized their conclusion to include other 02-agonists and the new long-acting drugs. The design, interpretation, and conclusions of this study have been criticized.7 '8 In a recent publication the same study is presented, but now in more detail showing that the differences between treatment periods were small and of doubtful clinical significance.9"10 The results of extensive clinical trial programs with salmeterol and formoterol" also do not support the suggestions of the study by Sears et al. 6 The asthma exacerbation rate is possibly the most important measure of overall asthma control. The logical progression of the hypothesis of Sears et al, 6 namely that regular use of /32-agonists leads to a worsening of asthma control, would be for the rate of exacerbations to rise following the use of more potent, selective, longer-acting 02-agonists in place of shorter-acting drugs used regularly or on demand. We have recently reported two large 12-month studies conducted outside the United States where salmeterol, 50 ,ug twice a day has been compared with albuterol, 200 bations among patients taking salmeterol 6 and an exacerbation rate that tended to decline over the 12- month period (Fig 1) . These There is also no evidence of tachyphylaxis to the bronchodilating effects of salmeterol and formoterol in regular long-term treatment. In the study by Pearlman et al,15 the bronchodilator response to salmeterol was maintained throughout the 12-week period as reflected by the FEV, area under the curve for salmeterol at each of the four evaluations. Several studies have shown no tolerance to the bronchodilating effects of inhaled albuterol in patients receiving regular salmeterol or formoterol for up to a year. [22] [23] [24] [25] In one of these studies,24 18 patients participated in a comparison of albuterol, 200 Mg twice a day with formoterol, 12 Mg twice a day. Of these 18 patients, 10 were randomly allocated to treatment with formoterol and 8 to treatment with albuterol. After 1, 2, and 3 months, patients were allowed to shift over to the alternative treatment if they were not satisfied with their asthma control. After 1 year, 13 of the 16 patients who completed the study were still using formoterol, for which they expressed a significant long-lasting preference. Dose-response curves for inhaled albuterol, recorded repeatedly during the study, showed no evidence of tachyphylaxis.24
In another 12-month study23 involving 11 asthmatic patients taking salmeterol, 50 Mg twice a day, cumulative dose-response curves to inhaled albuterol were performed prior to, and after 3, 6, 9, and 12 months' treatment. Patient response to albuterol was well maintained over the 12-month period and showed no signs of tolerance. In the absence of any pretrial run-in period, however, during which 02-agonist treatment was prohibited, the only definitive conclusion that may be drawn by this study is that salmeterol does not induce greater tolerance than any other /2-agonist.
Salmeterol has not only been shown to exert a significant beneficial effect on lung function by comparison with placebo and other bronchodilators but has also been compared with increasing the dose of inhaled glucocorticosteroid. In two studies sponsored by a manufacturer (Glaxo),28,29 salmeterol has also been compared with increased doses of inhaled glucocorticosteroid in patients who remained symptomatic while receiving low or high doses of inhaled beclomethasone dipropionate (BDP). One of these two studies28 compared the effects of adding salmeterol to the treatment regimen of 429 asthmatic patients who remained symptomatic while receiving 200 ,ug of BDP twice daily, with that of more than doubling the dose of BDP to 500 gg twice daily. The results, in terms of both lung function and symptoms, were consistently better in the salmeterol/corticosteroid group than in the higher-dose BDP group. There were no differences between the two groups in unwanted effects or exacerbations of asthma, indicating that, for this group of patients, regular salmeterol treatment was not associated with any evidence of deteriorating asthma control over a 6-month period and was better than increasing the dose of inhaled corticosteroids at improving lung function.
Similar results were obtained in the second study in patients with initially more severe asthma. after patients inhaled a single dose of formoterol. 42 Most published studies examining the effects of long-term dosing with long-acting d-agonists on bronchial reactivity have used salmeterol,4347 the only ,02-agonist shown to reduce the maximal response plateau to methacholine challenge.46 None of these studies shows evidence of rebound hyperresponsiveness after maintenance treatment and no tolerance has been seen to the acute bronchodilator effect after long-term dosing. One study46 comparing salmeterol, 50 ,g twice daily, with placebo over an 8-week period found evidence of a partial reduction in the short-term protection afforded against methacholine challenge, 1 h after dosing. After 4 and 8 weeks' treatment, PC20 was reduced from 3.3 to 1.0 doubling doses, a reduction that nevertheless constituted a significant protective effect. This degree of protection is of similar magnitude to that reported by the same workers examining the effects of regular use of inhaled corticosteroids. 48 The results of this study should be contrasted with those of Booth and colleagues47 who looked at protection against methacholine challenge 12 h after treatment in patients taking salmeterol, 50 Mg twice daily for 8 weeks.
Their results showed no reduction in protection throughout an 8-week period.
In another study, formoterol was shown to offer well-maintained protection against histamine-induced airway obstruction during 3 and oral corticosteroids. The study found nothing to indicate that regular treatment over a 4-month period with either salmeterol or albuterol was associated with an incidence of asthma deaths in excess of that predicted for the study population (14 vs 15) . The results demonstrated the importance of recognizing the symptoms of deteriorating asthma and giving appropriate treatment with inhaled and oral steroids. Physicians and patients alike should be aware that asthmatics who require increasing doses of shortacting 13-agonists to relieve symptoms are at risk of death. When Castle's results were debated after publication,53-58 it was noted that the study had a relatively low power to detect a difference in asthma deaths.54 As the authors of this study pointed out,56 however, it would not have been feasible to mount and complete a larger study in a reasonable time frame. Another concern, expressed by Sears and Taylor,57 was the distribution of deaths among the younger patients involved in the study. Again, the authors explained58 that the study included a relatively large proportion of younger patients by comparison with older patients, an age distribution that was reflected in the distribution of deaths.
In addition to the data provided by Castle et al,52 the safety of salmeterol in clinical use in the United Kingdom has been studied in an independent prescription event monitoring study by the Drug Safety Research Unit in Southampton, United Kingdom.59 This study monitored exposure data based on prescriptions for salmeterol and was an attempt to provide safety data on the drug based on information gained from "real life" general medical use. In a cohort of 15,407 patients who were prescribed salmeterol for at least 1 year, there were 39 asthma-related deaths among patients who had been taking salmeterol during the last month of their life and 73 asthma-related deaths overall. These figures are considerably lower than the authors first estimated and indicate that the mortality rate was higher in the early part of the study. The authors suggest that these data reflect the fact that when salmeterol was first marketed in the United Kingdom, general practitioners prescribed it for patients with particularly severe and unstable asthma. The mean age of patients dying in this study was 60.5 years, which does not suggest that salmeterol was associated with a greater risk in younger patients.
The methods outlined above probably constitute the best techniques available to monitor the safety of new drugs and identify possible concerns not recorded in preregistration studies. However, useful information can sometimes also be gained from the case reports from individual clinicians. In relation to salmeterol, there have been at least two publications that are relevant.60'61 Clark and colleagues60 reported three cases of respiratory arrest in asthmatics recently prescribed salmeterol and expressed concern that there might be a relationship between the two events. However, as Shale62 pointed out in a subsequent letter, in each case, there were other plausible explanations for a deterioration in the patients' asthma and that these case reports were circumstantial. In the other case report by Wilkinson and colleagues,61 the authors described six cases of acute bronchospasm induced by inhaling salmeterol by metered-dose inhaler but not by a dry powder formulation. This, however, seems to be a rare event based on data from a double-blind, parallel group study in 11,580 patients that compared salmeterol placebo aerosols containing either lecithin or oleic acid with a standard salmeterol aerosol containing lecithin dispersant. 63 The incidence of paradoxic bronchospasm after salmeterol was 1.1 %, which was significantly lower than either of the placebo groups.
An alternative way of looking for an association with asthma mortality is to examine asthma mortality figures in England and Wales since salmeterol has been available for use. Given the level of patient exposure to salmeterol, an overt effect on overall asthma 
CONCLUSION
To our knowledge, there have been no studies published that unequivocally demonstrate a deleterious effect on asthma morbidity and mortality of regular p2-agonist use. Long-acting 32-agonists might be reasonably expected to exhibit more prominently any deleterious effects if these do occur. However, studies with both formoterol and salmeterol have not shown any evidence of reduced asthma control, deterioration in lung function, or increased airway responsiveness (Tables 1 and 2 ). Furthermore, there is no evidence of a relationship between these drugs and increased asthma mortality. On the contrary, large well-designed clinical trials have shown improvements in lung function and overall asthma control and strongly contradict the hypothetical arguments that propose that 32-agonists have a deleterious effect on asthma morbidity and mortality.
